市場調査レポート
商品コード
1499443
医薬品スクリーニング市場:製品タイプ別、サンプルタイプ別、エンドユーザー別-2024~2030年の世界予測Drug Screening Market by Product (Consumables, Instruments, Services), Sample Type (Breath Samples, Hair Samples, Oral Fluid Samples), End User - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
医薬品スクリーニング市場:製品タイプ別、サンプルタイプ別、エンドユーザー別-2024~2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
|
医薬品スクリーニング市場規模は、2023年に86億6,000万米ドルと推定され、2024年には98億9,000万米ドルに達し、CAGR 14.42%で2030年には222億5,000万米ドルに達すると予測されます。
医薬品スクリーニングとは、尿、血液、毛髪、唾液などの生体サンプルを検査し、違法薬物や処方薬物、その代謝物の存在を特定するプロセスです。このプロセスは、雇用、刑事司法、スポーツ、依存症の治療など、さまざまな場面で一般的に使用され、個人が薬物政策を遵守していること、または禁止物質がないことを確認します。職場における安全性とコンプライアンスの向上、処方薬と非処方薬の世界の消費量の増加、薬物検査を義務付ける政府による厳格な規制と組織の方針が大きな推進力となっています。しかし、高度な検査技術には高いコストがかかり、薬物検出窓にはばらつきがあるため、採用が妨げられる可能性があります。とはいえ、より高感度かつ迅速な検査の開拓と、モバイルおよびオンサイトの薬物検査サービスに対するニーズの高まりは、市場成長の潜在的機会を生み出すと予想されます。
主な市場の統計 | |
---|---|
基準年[2023] | 86億6,000万米ドル |
予測年[2024] | 98億9,000万米ドル |
予測年 [2030] | 222億5,000万米ドル |
CAGR(%) | 14.42% |
地域別インサイト
アジア太平洋地域は、職場の安全性と効率性、公衆衛生に対する意識の高まりにより、医薬品スクリーニングで大幅な成長を遂げています。APAC諸国は多様な人口を抱え、薬物乱用の割合も様々であるため、薬物検査サービスの必要性は地域によって異なります。政府機関は薬物乱用を抑制するための取り組みを進めており、医薬品スクリーニング機器やサービスに対するニーズが高まっています。アメリカ地域は、厳格な規制要件と職場安全規制の施行により、医薬品スクリーニングの発展市場の一つとなっています。オピオイド危機により、薬物検査への注目がさらに高まっています。南北アメリカ地域では、薬物検査手法やキットの技術革新を反映し、特許登録が進化し続けています。EU諸国は公衆衛生と職場の安全性に強く注目しており、医薬品スクリーニングの実践を管理する厳格な法律があります。データ保護規制は職場の薬物検査管理にも影響を与えます。麻薬取締法が厳しい中東諸国では、医薬品スクリーニングの市場が変動しており、しばしば政府の政策によって義務付けられています。アフリカの医薬品スクリーニング市場は台頭しつつあり、医薬品スクリーニングに対する認識とニーズは、主に公衆衛生キャンペーンと国際的な職場安全基準の影響を受けて高まっています。欧州諸国は研究開発に多大な投資を行っており、その結果、高い精度と信頼性基準を満たす高度な医薬品スクリーニング技術が開発されています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、医薬品スクリーニング市場におけるベンダーのポジショニングを評価するために不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、医薬品スクリーニング市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、医薬品スクリーニング市場における現在の立ち位置を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[199 Pages Report] The Drug Screening Market size was estimated at USD 8.66 billion in 2023 and expected to reach USD 9.89 billion in 2024, at a CAGR 14.42% to reach USD 22.25 billion by 2030.
Drug screening is the process of checking biological samples, such as urine, blood, hair, or saliva, to identify the existence of illegal or prescription drugs or their metabolites. This process is commonly used in various contexts, including employment, criminal justice, sports, and treatment of addiction, ensuring individuals are compliant with drug policies or are free from prohibited substances. Increased safety and compliance in workplaces, increasing consumption of both prescription and non-prescription drugs worldwide, and strict regulations by governments and organizational policies mandating drug testing are significant drivers. However, the high costs of advanced testing technologies and variability in drug detection windows can deter adoption. Nevertheless, the development of more sensitive and faster tests and the growing need for mobile and on-site drug testing services are expected to create potential opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 8.66 billion |
Estimated Year [2024] | USD 9.89 billion |
Forecast Year [2030] | USD 22.25 billion |
CAGR (%) | 14.42% |
Regional Insights
The Asia-Pacific region has seen substantial growth in drug screening due to increasing awareness about the safety and efficiency of workplaces and public health. APAC countries have diverse populations and exhibit varying rates of substance abuse, which influences the need for drug testing services differently across the region. Government agencies have advanced their efforts in curbing drug abuse, translating into a higher need for drug screening devices and services. The Americas region is one of the evolved markets for drug screening due to strict regulatory requirements and the enforcement of workplace safety regulations. The opioid crisis has further heightened the focus on drug testing. The Americas region continues evolving in patent registrations, reflecting ongoing drug testing methodologies and kit innovations. EU countries focus strongly on public health and workplace safety, with rigorous laws governing drug screening practices. The data protection regulation also impacts the administration of workplace drug testing. With stringent anti-drug laws, countries in the Middle East have a variable market for drug screening, often mandated by government policies. Africa's drug screening market is emerging, with an increasing awareness and need for drug screening primarily influenced by public health campaigns and international workplace safety standards. European countries invest significantly in research and development, which has led to advanced drug screening technologies designed to meet high accuracy and reliability standards.
Market Insights
The market dynamics represent an ever-changing landscape of the Drug Screening Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug Screening Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug Screening Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Innovative Partnership Launches Virtual Drug Screening Platform
eMed, a digital health company, partnered with i3Screen, an established provider of drug screening solutions, to introduce virtual drug testing services. This new platform is designed to facilitate remote drug screening, utilizing eMed's patented technology to ensure the integrity and confidentiality of the testing process. The service is tailored for employers and organizations looking to implement drug testing efficiently while minimizing the need for physical interactions. This partnership enhances the accessibility and effectiveness of drug testing programs and aligns with current trends toward more digital and remote healthcare solutions. [Published On: 2024-05-15]
Launch of Accurate Background's Advanced Drug and Health Screening Services
Accurate Background, a provider of background and identity services, has recently expanded its offerings by launching a new, enhanced drug and health screening service. This service is designed to accommodate the growing demand for efficient and comprehensive employee screening processes. With this advancement, the company introduces a streamlined platform integrating enhanced drug testing methods with robust health screening capabilities. Employers benefit from this service as it provides a more efficient way to conduct pre-employment health assessments, enabling faster and more informed hiring decisions. This initiative underscores Accurate Background's commitment to innovating within the industry and enhances its ability to support employers in maintaining a safe and compliant workplace. [Published On: 2024-04-04]
bioXcelerate Revolutionizes Drug Discovery with AI-Powered Screening Tool
bioXcelerate announced the launch of a cutting-edge artificial intelligence (AI) tool designed to expedite the drug discovery process significantly. This innovative technology aims to streamline the early stages of drug development by enhancing the screening of chemical compounds and expediting the identification of promising drug candidates. By leveraging AI, bioXcelerate anticipates reducing the time and costs traditionally associated with these phases, potentially accelerating the timeline for bringing new drugs to market. This breakthrough is instrumental in ushering in a new era of faster, more efficient drug discovery, particularly beneficial in addressing rapidly evolving global health challenges. [Published On: 2024-03-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug Screening Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Drug Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuSourceHR, Inc., ACM Global Laboratories, Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Clinical Reference Laboratory, Inc., Cordant Health Solutions, Danaher Corporation, Dragerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., Intoximeters, Inc., Laboratory Corporation of America Holdings, Lifeloc Technologies, Inc., Merck KGaA, Omega Laboratories, Inc. by Juno Pharmaceuticals Corp., OraSure Technologies, Inc., Pfizer Inc., Premier Biotech, LLC, Psychemedics Corporation, Quest Diagnostics Incorporated, Sartorius AG, Securetec Detektions-Systeme AG, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., and United States Drug Testing Laboratories, Inc..
Market Segmentation & Coverage